Use of Intramuscular Chlorpromazine Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Youth
In the inpatient psychiatric setting, one treatment strategy used to manage acute agitation in youth includes administration of IM antipsychotics. The aim of this study was to compare the effectiveness and safety of IM chlorpromazine versus IM olanzapine in treating aggression in youth. We conducted...
Gespeichert in:
Veröffentlicht in: | The journal of pediatric pharmacology and therapeutics 2021, Vol.26 (1), p.33-41 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 41 |
---|---|
container_issue | 1 |
container_start_page | 33 |
container_title | The journal of pediatric pharmacology and therapeutics |
container_volume | 26 |
creator | Snyder, Sabrina Domicoli Williams, Andrew Mitchell, Melissa Kneebusch, Jamie |
description | In the inpatient psychiatric setting, one treatment strategy used to manage acute agitation in youth includes administration of IM antipsychotics. The aim of this study was to compare the effectiveness and safety of IM chlorpromazine versus IM olanzapine in treating aggression in youth.
We conducted a retrospective chart review of patients younger than 18 years hospitalized in the inpatient psychiatric unit who received either IM chlorpromazine or IM olanzapine for acute agitation. Demographic, efficacy, and tolerability data were collected using the electronic health record EPIC. The primary outcome was change from baseline to end point in the Behavioral Activity Rating Scale (BARS) score. BARS was applied retrospectively using nursing and physician documentation to evaluate for clinical response.
Among 145 patients who met the inclusion criteria, 72 received IM chlorpromazine, compared with 73 who received IM olanzapine. The mean change in BARS score (before and after IM antipsychotic) was greater with olanzapine (3.58 ± 0.99) than with chlorpromazine (3.07 ± 1.18, p = 0.006). The target BARS score of 4 was achieved more frequently with chlorpromazine (45.8%) than with olanzapine (24.7%, p < 0.008). Coadministration of IM diphenhydramine occurred significantly more often in the olanzapine group than in the chlorpromazine group (71.2% vs 36.1%, p < 0.001).
Management of acute agitation with IM olanzapine resulted in a greater change in BARS score, despite more youth requiring coadministration with diphenhydramine. In comparison, IM chlorpromazine demonstrated a higher likelihood of returning patients to baseline. Study results suggest tolerability of IM chlorpromazine and olanzapine. |
doi_str_mv | 10.5863/1551-6776-26.1.33 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7792138</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2476844002</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3143-b95706333c84eee8fa1452211f6d1cbda277fe682482de329dd0c736889650373</originalsourceid><addsrcrecordid>eNpdUU1r3DAQFaWlWbb5Ab0EHXPxVtLIknwpLEvbBBJyaUp7Elp5vOtgSxvJDjS3_vPYJF2azmUY3ps3H4-Qj5ytSqPgEy9LXiitVSHUiq8A3pCFAOAFSPPzLVkc8RNymvMdm0JKzUr5npwASCFlZRbkz21GGht6GYbk-jH7sXOJbvZdTIcUe_fYBqQ_MOUx_8e56Vx4dIcZb2Kiwx7ptQtuhz2GYZZc-3FAut61gxvaGKgL9VTtEuY8l22gv-I47D-Qd43rMp6-5CW5_frl--aiuLr5drlZXxUeuIRiW5WaKQDwRiKiaRyXpRCcN6rmfls7oXWDyghpRI0gqrpmXoMyplIlAw1L8vlZ9zBue6w9ztd09pDa3qXfNrrWvkZCu7e7-GC1rgQHMwmcvwikeD9iHmzfZo_d9AeMY7ZCamWkZExMVP5M9SnmnLA5juHMzu7Z2R07u2OFstxOdy3J2b_7HTv-egVPMkKXvw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476844002</pqid></control><display><type>article</type><title>Use of Intramuscular Chlorpromazine Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Youth</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Snyder, Sabrina Domicoli ; Williams, Andrew ; Mitchell, Melissa ; Kneebusch, Jamie</creator><creatorcontrib>Snyder, Sabrina Domicoli ; Williams, Andrew ; Mitchell, Melissa ; Kneebusch, Jamie</creatorcontrib><description>In the inpatient psychiatric setting, one treatment strategy used to manage acute agitation in youth includes administration of IM antipsychotics. The aim of this study was to compare the effectiveness and safety of IM chlorpromazine versus IM olanzapine in treating aggression in youth.
We conducted a retrospective chart review of patients younger than 18 years hospitalized in the inpatient psychiatric unit who received either IM chlorpromazine or IM olanzapine for acute agitation. Demographic, efficacy, and tolerability data were collected using the electronic health record EPIC. The primary outcome was change from baseline to end point in the Behavioral Activity Rating Scale (BARS) score. BARS was applied retrospectively using nursing and physician documentation to evaluate for clinical response.
Among 145 patients who met the inclusion criteria, 72 received IM chlorpromazine, compared with 73 who received IM olanzapine. The mean change in BARS score (before and after IM antipsychotic) was greater with olanzapine (3.58 ± 0.99) than with chlorpromazine (3.07 ± 1.18, p = 0.006). The target BARS score of 4 was achieved more frequently with chlorpromazine (45.8%) than with olanzapine (24.7%, p < 0.008). Coadministration of IM diphenhydramine occurred significantly more often in the olanzapine group than in the chlorpromazine group (71.2% vs 36.1%, p < 0.001).
Management of acute agitation with IM olanzapine resulted in a greater change in BARS score, despite more youth requiring coadministration with diphenhydramine. In comparison, IM chlorpromazine demonstrated a higher likelihood of returning patients to baseline. Study results suggest tolerability of IM chlorpromazine and olanzapine.</description><identifier>ISSN: 1551-6776</identifier><identifier>EISSN: 2331-348X</identifier><identifier>DOI: 10.5863/1551-6776-26.1.33</identifier><identifier>PMID: 33424498</identifier><language>eng</language><publisher>United States: Pediatric Pharmacy Advocacy Group</publisher><subject>Clinical Investigations</subject><ispartof>The journal of pediatric pharmacology and therapeutics, 2021, Vol.26 (1), p.33-41</ispartof><rights>Copyright Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2021.</rights><rights>Pediatric Pharmacy Association. All rights reserved. For permissions, email: 2021 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3143-b95706333c84eee8fa1452211f6d1cbda277fe682482de329dd0c736889650373</citedby><cites>FETCH-LOGICAL-c3143-b95706333c84eee8fa1452211f6d1cbda277fe682482de329dd0c736889650373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792138/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792138/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,4025,27928,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33424498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Snyder, Sabrina Domicoli</creatorcontrib><creatorcontrib>Williams, Andrew</creatorcontrib><creatorcontrib>Mitchell, Melissa</creatorcontrib><creatorcontrib>Kneebusch, Jamie</creatorcontrib><title>Use of Intramuscular Chlorpromazine Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Youth</title><title>The journal of pediatric pharmacology and therapeutics</title><addtitle>J Pediatr Pharmacol Ther</addtitle><description>In the inpatient psychiatric setting, one treatment strategy used to manage acute agitation in youth includes administration of IM antipsychotics. The aim of this study was to compare the effectiveness and safety of IM chlorpromazine versus IM olanzapine in treating aggression in youth.
We conducted a retrospective chart review of patients younger than 18 years hospitalized in the inpatient psychiatric unit who received either IM chlorpromazine or IM olanzapine for acute agitation. Demographic, efficacy, and tolerability data were collected using the electronic health record EPIC. The primary outcome was change from baseline to end point in the Behavioral Activity Rating Scale (BARS) score. BARS was applied retrospectively using nursing and physician documentation to evaluate for clinical response.
Among 145 patients who met the inclusion criteria, 72 received IM chlorpromazine, compared with 73 who received IM olanzapine. The mean change in BARS score (before and after IM antipsychotic) was greater with olanzapine (3.58 ± 0.99) than with chlorpromazine (3.07 ± 1.18, p = 0.006). The target BARS score of 4 was achieved more frequently with chlorpromazine (45.8%) than with olanzapine (24.7%, p < 0.008). Coadministration of IM diphenhydramine occurred significantly more often in the olanzapine group than in the chlorpromazine group (71.2% vs 36.1%, p < 0.001).
Management of acute agitation with IM olanzapine resulted in a greater change in BARS score, despite more youth requiring coadministration with diphenhydramine. In comparison, IM chlorpromazine demonstrated a higher likelihood of returning patients to baseline. Study results suggest tolerability of IM chlorpromazine and olanzapine.</description><subject>Clinical Investigations</subject><issn>1551-6776</issn><issn>2331-348X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdUU1r3DAQFaWlWbb5Ab0EHXPxVtLIknwpLEvbBBJyaUp7Elp5vOtgSxvJDjS3_vPYJF2azmUY3ps3H4-Qj5ytSqPgEy9LXiitVSHUiq8A3pCFAOAFSPPzLVkc8RNymvMdm0JKzUr5npwASCFlZRbkz21GGht6GYbk-jH7sXOJbvZdTIcUe_fYBqQ_MOUx_8e56Vx4dIcZb2Kiwx7ptQtuhz2GYZZc-3FAut61gxvaGKgL9VTtEuY8l22gv-I47D-Qd43rMp6-5CW5_frl--aiuLr5drlZXxUeuIRiW5WaKQDwRiKiaRyXpRCcN6rmfls7oXWDyghpRI0gqrpmXoMyplIlAw1L8vlZ9zBue6w9ztd09pDa3qXfNrrWvkZCu7e7-GC1rgQHMwmcvwikeD9iHmzfZo_d9AeMY7ZCamWkZExMVP5M9SnmnLA5juHMzu7Z2R07u2OFstxOdy3J2b_7HTv-egVPMkKXvw</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Snyder, Sabrina Domicoli</creator><creator>Williams, Andrew</creator><creator>Mitchell, Melissa</creator><creator>Kneebusch, Jamie</creator><general>Pediatric Pharmacy Advocacy Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2021</creationdate><title>Use of Intramuscular Chlorpromazine Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Youth</title><author>Snyder, Sabrina Domicoli ; Williams, Andrew ; Mitchell, Melissa ; Kneebusch, Jamie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3143-b95706333c84eee8fa1452211f6d1cbda277fe682482de329dd0c736889650373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical Investigations</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Snyder, Sabrina Domicoli</creatorcontrib><creatorcontrib>Williams, Andrew</creatorcontrib><creatorcontrib>Mitchell, Melissa</creatorcontrib><creatorcontrib>Kneebusch, Jamie</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of pediatric pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Snyder, Sabrina Domicoli</au><au>Williams, Andrew</au><au>Mitchell, Melissa</au><au>Kneebusch, Jamie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Intramuscular Chlorpromazine Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Youth</atitle><jtitle>The journal of pediatric pharmacology and therapeutics</jtitle><addtitle>J Pediatr Pharmacol Ther</addtitle><date>2021</date><risdate>2021</risdate><volume>26</volume><issue>1</issue><spage>33</spage><epage>41</epage><pages>33-41</pages><issn>1551-6776</issn><eissn>2331-348X</eissn><abstract>In the inpatient psychiatric setting, one treatment strategy used to manage acute agitation in youth includes administration of IM antipsychotics. The aim of this study was to compare the effectiveness and safety of IM chlorpromazine versus IM olanzapine in treating aggression in youth.
We conducted a retrospective chart review of patients younger than 18 years hospitalized in the inpatient psychiatric unit who received either IM chlorpromazine or IM olanzapine for acute agitation. Demographic, efficacy, and tolerability data were collected using the electronic health record EPIC. The primary outcome was change from baseline to end point in the Behavioral Activity Rating Scale (BARS) score. BARS was applied retrospectively using nursing and physician documentation to evaluate for clinical response.
Among 145 patients who met the inclusion criteria, 72 received IM chlorpromazine, compared with 73 who received IM olanzapine. The mean change in BARS score (before and after IM antipsychotic) was greater with olanzapine (3.58 ± 0.99) than with chlorpromazine (3.07 ± 1.18, p = 0.006). The target BARS score of 4 was achieved more frequently with chlorpromazine (45.8%) than with olanzapine (24.7%, p < 0.008). Coadministration of IM diphenhydramine occurred significantly more often in the olanzapine group than in the chlorpromazine group (71.2% vs 36.1%, p < 0.001).
Management of acute agitation with IM olanzapine resulted in a greater change in BARS score, despite more youth requiring coadministration with diphenhydramine. In comparison, IM chlorpromazine demonstrated a higher likelihood of returning patients to baseline. Study results suggest tolerability of IM chlorpromazine and olanzapine.</abstract><cop>United States</cop><pub>Pediatric Pharmacy Advocacy Group</pub><pmid>33424498</pmid><doi>10.5863/1551-6776-26.1.33</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1551-6776 |
ispartof | The journal of pediatric pharmacology and therapeutics, 2021, Vol.26 (1), p.33-41 |
issn | 1551-6776 2331-348X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7792138 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Clinical Investigations |
title | Use of Intramuscular Chlorpromazine Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Youth |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T11%3A55%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Intramuscular%20Chlorpromazine%20Versus%20Intramuscular%20Olanzapine%20for%20the%20Management%20of%20Acute%20Agitation%20and%20Aggression%20in%20Youth&rft.jtitle=The%20journal%20of%20pediatric%20pharmacology%20and%20therapeutics&rft.au=Snyder,%20Sabrina%20Domicoli&rft.date=2021&rft.volume=26&rft.issue=1&rft.spage=33&rft.epage=41&rft.pages=33-41&rft.issn=1551-6776&rft.eissn=2331-348X&rft_id=info:doi/10.5863/1551-6776-26.1.33&rft_dat=%3Cproquest_pubme%3E2476844002%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476844002&rft_id=info:pmid/33424498&rfr_iscdi=true |